Hughes Katie, Sumaruth Yovan Ram Kurrun, Mohammed Elmahi, Sant Bakshsingh Vibhootee
Medicine, North Manchester General Hospital, Manchester, GBR.
Internal Medicine, North Manchester General Hospital, Manchester, GBR.
Cureus. 2024 Sep 21;16(9):e69844. doi: 10.7759/cureus.69844. eCollection 2024 Sep.
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that has gained recent popularity in its effective management of type 2 diabetes mellitus (T2DM) and obesity. Minimal evidence has reported the link between Semaglutide use and acute pancreatitis. In this case report, we discuss the case of a 36-year-old female presenting to the Emergency Department with sudden-onset epigastric pain, subsequently diagnosed with acute pancreatitis. Moreover, she had recently started subcutaneous semaglutide injections for weight loss, which she had procured from one of her acquaintances without seeking medical advice. Semaglutide was thus stopped and her lipase levels normalized with significant improvement of her symptoms, making semaglutide the likely causative factor for her acute pancreatitis. Given the increased use of GLP-1RA, we aim to increase awareness among patients taking this medication whether prescribed or not and increase clinician awareness when prescribing this medication.
司美格鲁肽是一种胰高血糖素样肽-1受体激动剂（GLP-1RA），最近在有效管理2型糖尿病（T2DM）和肥胖症方面受到广泛关注。关于使用司美格鲁肽与急性胰腺炎之间的关联，目前报道的证据极少。在本病例报告中，我们讨论了一名36岁女性因突发上腹部疼痛就诊于急诊科，随后被诊断为急性胰腺炎的病例。此外，她最近开始自行从熟人处获取皮下注射司美格鲁肽用于减肥，未寻求医疗建议。因此停用了司美格鲁肽，她的脂肪酶水平恢复正常，症状也有显著改善，这使得司美格鲁肽成为她急性胰腺炎的可能病因。鉴于GLP-1RA的使用增多，我们旨在提高服用这种药物的患者（无论是否为处方用药）的认识，并提高临床医生在开具此药时的意识。
